Publication

Clinical epidemiology of the global expansion of klebsiella pneumoniae carbapenemases

Munoz-Price, L Silvia
; 
Poirel, Laurent
; 
Bonomo, Robert A
; 
Schwaber, Mitchell J
; 
Daikos, George L
; 
Cormican, Martin
; 
Cornaglia, Giuseppe
; 
Garau, Javier
; 
Gniadkowski, Marek
; 
Hayden, Mary K
... show 10 more
Identifiers
http://hdl.handle.net/10379/13025
https://doi.org/10.13025/28244
Repository DOI
10.1016/s1473-3099(13)70190-7
Publication Date
2013-09-01
Keywords
hydrolyzing beta-lactamase, kpc-producing enterobacteriaceae, gram-negative bacilli, acute-care facilities, new-york-city, escherichia-coli, pseudomonas-aeruginosa, resistant enterobacteriaceae, k.-pneumoniae, united-states
Type
Article
Downloads
Show all metadata
Citation
Munoz-Price, L Silvia; Poirel, Laurent; Bonomo, Robert A; Schwaber, Mitchell J; Daikos, George L; Cormican, Martin; Cornaglia, Giuseppe; Garau, Javier; Gniadkowski, Marek; Hayden, Mary K; Kumarasamy, Karthikeyan; Livermore, David M; Maya, Juan J; Nordmann, Patrice; Patel, Jean B; Paterson, David L; Pitout, Johann; Villegas, Maria Virginia; Wang, Hui; Woodford, Neil; Quinn, John P (2013). Clinical epidemiology of the global expansion of klebsiella pneumoniae carbapenemases. The Lancet Infectious Diseases 13 (9), 785-796
Abstract
Klebsiella pneumoniae carbapenemases (KPCs) were originally identified in the USA in 1996. Since then, these versatile beta-lactamases have spread internationally among Gram-negative bacteria, especially K pneumoniae, although their precise epidemiology is diverse across countries and regions. The mortality described among patients infected with organisms positive for KPC is high, perhaps as a result of the limited antibiotic options remaining (often colistin, tigecycline, or aminoglycosides). Triple drug combinations using colistin, tigecycline, and imipenem have recently been associated with improved survival among patients with bacteraemia. In this Review, we summarise the epidemiology of KPCs across continents, and discuss issues around detection, present antibiotic options and those in development, treatment outcome and mortality, and infection control. In view of the limitations of present treatments and the paucity of new drugs in the pipeline, infection control must be our primary defence for now.
Funder
Publisher
Elsevier BV
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland
cbn
Collections
Externally hosted open access publications with University of Galway authors (2)